Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

Video

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

Related Videos
Paul E. Dato, MD, an expert on prostate cancer
Charles Parker, MD, answers a question during a Zoom video interview
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Related Content
© 2023 MJH Life Sciences

All rights reserved.